Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,553 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: IBD Clear all
Completed Phase 4 Interventional Results available

Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)

NCT03723447
View directory record Official record
Conditions
Pain, Postoperative, Crohn Disease, Inflammatory Bowel Diseases, Colorectal Cancer, Gastrointestinal Cancer, Gastrointestinal Disease, Digestive System Disease, Pain, Pain, Neuropathic, Intestinal Disease
Interventions
Liposomal bupivacaine, Bupivacaine/epinephrine/dexamethasone
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 24, 2026, 4:23 PM EDT
Terminated Early Phase 1 Interventional

Maintenance Dosing of Vitamin D in Crohn's Disease

NCT03615378
View directory record Official record
Conditions
Crohns Disease, Vitamin D Deficiency
Interventions
5000 IU D3, 1000 IU D3, Placebo
Dietary Supplement
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 24, 2026, 4:23 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Safety and Feasibility of ActivSightTM in Human

NCT04633512
View directory record Official record
Conditions
Acute Cholecystitis, Colorectal Cancer, Diverticulitis, Colonic, Obesity, Morbid, Inflammatory Bowel Diseases
Interventions
ActivSight
Device
Lead sponsor
Activ Surgical
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
3
States / cities
Buffalo, New York • Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 24, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

SH-DS01 on Fecal Metagenomic Stability

NCT04598295
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
DS-01
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 24, 2026, 4:23 PM EDT
Not listed Phase 2Phase 3 Interventional

A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females

NCT00547469
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
DDP733
Drug
Lead sponsor
Dynogen Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
62
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 53 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2008 · Synced Oct 24, 2026, 4:23 PM EDT
Recruiting Not applicable Interventional

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

NCT05230173
View directory record Official record
Conditions
Ulcerative Colitis, Crohn Disease
Interventions
Pragmatic
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
24
States / cities
Scottsdale, Arizona • Irvine, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 24, 2026, 4:23 PM EDT
Recruiting No phase listed Observational

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

NCT04751396
View directory record Official record
Conditions
Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Enteropathic Arthritis, Enteropathic Spondylitis, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis
Interventions
Best Practice, Educational Intervention, Interview, Questionnaire Administration, Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 24, 2026, 4:23 PM EDT
Not yet recruiting Not applicable Interventional

VR Therapies for IBD

NCT07590518
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn Disease (CD), Anxiety
Interventions
Distraction VR, VR/AI CBT
Device
Lead sponsor
Brennan Spiegel
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 24, 2026, 4:23 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

NCT01203631
View directory record Official record
Conditions
Inflammation, Crohn's Disease
Interventions
NNC 0142-0000-0002, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
Anaheim, California • Lakewood, Colorado • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 24, 2026, 4:23 PM EDT
Completed Phase 3 Interventional Results available

ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

NCT05507203
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ABX464, Placebo
Drug
Lead sponsor
Abivax S.A.
Industry
Eligibility
16 Years and older
Enrollment
639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
54
States / cities
Dothan, Alabama • Guntersville, Alabama • Homewood, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 24, 2026, 4:23 PM EDT
Completed Phase 1 Interventional

Pediatric MSC-AFP Sub-study for Crohn's Fistula

NCT03449069
View directory record Official record
Conditions
Fistula in Ano, Crohn Disease
Interventions
MSC-AFP
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
12 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 24, 2026, 4:23 PM EDT
Recruiting Phase 1 Interventional

R-3750 in Patients With Mild to Moderate Ulcerative Colitis

NCT05666960
View directory record Official record
Conditions
Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic, Ulcerative Colitis
Interventions
R-3750
Drug
Lead sponsor
Rise Therapeutics LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Valencia, California • Miami, Florida • Plantation, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 24, 2026, 4:23 PM EDT
Completed Phase 2 Interventional

Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease

NCT00101946
View directory record Official record
Conditions
Crohn's Disease
Interventions
683699
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Garden Grove, California • Roseville, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 24, 2026, 4:23 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

The Role of Gut Microbiome in Predicting Comorbidities and Complications in Children With Inflammatory Bowel Disease

NCT05652491
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 20 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 24, 2026, 4:23 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Chondroitin Sulfate for Crohn's Disease

NCT01245088
View directory record Official record
Conditions
Crohn's Disease
Interventions
chondroitin sulfate
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 31, 2012 · Synced Oct 24, 2026, 4:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dietary Treatment of Crohn's Disease

NCT00343642
View directory record Official record
Conditions
Crohn's Disease, Inflammatory Bowel Disease
Interventions
Active fructo-oligosaccharide, Placebo fructo-oligosaccharide, Diet
Drug · Dietary Supplement
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Macon, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 24, 2026, 4:23 PM EDT
Completed Phase 3 Interventional

Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

NCT00077779
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
43
States / cities
La Jolla, California • San Francisco, California • Arvada, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2007 · Synced Oct 24, 2026, 4:23 PM EDT
Terminated Phase 3 Interventional

Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency

NCT04231279
View directory record Official record
Conditions
Abdominal Pain, Irritable Bowel Syndrome
Interventions
synthetic human secretin
Drug
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
6 Months to 18 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 24, 2026, 4:23 PM EDT
Terminated Phase 1Phase 2 Interventional

Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease

NCT04519697
View directory record Official record
Conditions
Rectovaginal Fistula, Crohn Disease, Crohn Disease of Vulva, Rectolabial; Fistula
Interventions
Mesenchymal Stem Cells, Placebo
Drug · Other
Lead sponsor
Anthony Lembo
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 24, 2026, 4:23 PM EDT
Completed Not applicable Interventional Results available

Crohn Disease Exclusion Diet After Single Medication De-escalation

NCT02472457
View directory record Official record
Conditions
Crohn Disease
Interventions
Crohn Disease Exclusion Diet, Free Diet
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 24, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

NCT02538341
View directory record Official record
Conditions
Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis, Psoriatic Arthritis, Psoriasis, Ankylosing Spondylitis, Enteropathic Arthritis, Crohn's Disease
Interventions
Herpes Zoster (HZ) Vaccine, Placebo
Biological · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
34
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 24, 2026, 4:23 PM EDT
Completed Early Phase 1 Interventional

Synergistic Effect of Vedolizumab and Pentoxifylline

NCT02953275
View directory record Official record
Conditions
Crohn Disease
Interventions
vedolizumab, Pentoxifylline, placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 24, 2026, 4:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early MRI Prediction of Crohns

NCT03340519
View directory record Official record
Conditions
Crohn Disease
Interventions
MR Imaging
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 25 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 24, 2026, 4:23 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

NCT03259334
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Ontamalimab, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
16 Years to 80 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
38
States / cities
Little Rock, Arkansas • Lancaster, California • Rialto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 24, 2026, 4:23 PM EDT